Exscientia plc (NASDAQ:EXAI - Get Free Report)'s share price traded up 6.9% on Monday . The company traded as high as $5.01 and last traded at $4.99. 341,928 shares were traded during trading, a decline of 50% from the average session volume of 686,375 shares. The stock had previously closed at $4.67.
Analysts Set New Price Targets
Separately, Morgan Stanley reiterated an "equal weight" rating and issued a $7.00 price objective on shares of Exscientia in a research note on Monday, April 22nd.
Read Our Latest Research Report on Exscientia
Exscientia Stock Up 7.1 %
The firm's 50-day simple moving average is $5.41 and its 200-day simple moving average is $5.81. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.22 and a current ratio of 6.22. The company has a market capitalization of $604.45 million, a price-to-earnings ratio of -3.38 and a beta of 0.82.
Exscientia (NASDAQ:EXAI - Get Free Report) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.02. The firm had revenue of $3.10 million for the quarter, compared to analyst estimates of $41.63 million. Exscientia had a negative return on equity of 36.44% and a negative net margin of 737.10%. Sell-side analysts forecast that Exscientia plc will post -1.76 earnings per share for the current year.
Institutional Investors Weigh In On Exscientia
Institutional investors and hedge funds have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale acquired a new stake in shares of Exscientia in the 3rd quarter valued at $344,000. Banque Pictet & Cie SA bought a new stake in Exscientia during the third quarter worth about $1,040,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Exscientia by 359.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company's stock worth $34,000 after buying an additional 4,104 shares in the last quarter. Platinum Investment Management Ltd. raised its stake in shares of Exscientia by 10.2% in the third quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company's stock valued at $19,866,000 after acquiring an additional 405,426 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in shares of Exscientia in the 4th quarter worth approximately $207,000. Institutional investors own 41.58% of the company's stock.
Exscientia Company Profile
(
Get Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
